Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

DANAHER CORPORATION

(DHR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Danaher : Bionity - Danaher To Acquire Aldevron

06/21/2021 | 10:43am EDT

Danaher Corporation announced that Danaher has entered into a definitive agreement to acquire privately-held Aldevron, for a cash purchase price of approximately $9.6 billion.

Danaher expects to finance the acquisition using cash on hand and/or proceeds from the issuance of commercial paper.

Founded in 1998 by Michael Chambers and John Ballantyne, Aldevron is headquartered in Fargo, North Dakota and employs approximately 600 people. Aldevron manufactures high-quality plasmid DNA, mRNA, and proteins, serving biotechnology and pharmaceutical customers across research, clinical and commercial applications. Aldevron will operate as a standalone operating company and brand within Danaher's Life Sciences segment.

Rainer M. Blair, Danaher President and Chief Executive Officer, said, 'We are thrilled to have Aldevron join Danaher's Life Sciences segment. For nearly 25 years, Aldevron has made tremendous contributions to the advancement of cell, gene and other novel therapies and vaccines. This acquisition will expand our capabilities into the important field of genomic medicine and help us support our customers and their critical mission to bring more life-saving therapies and vaccines to market faster.'

Michael Chambers, Aldevron Founder and Executive Chairman, added, 'Joining Danaher will help us expand our global reach and harness the power of the Danaher Business System to continue supporting our customers with best-in-class products and services. I'm incredibly excited for Aldevron to take this pivotal next step with Danaher and look forward to the tremendous impact we can make together in the expanding area of genomic medicine.'

The transaction is subject to customary conditions, including receipt of applicable regulatory approvals.

Contact:

Tel: 1-855-526-6737

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about DANAHER CORPORATION
08/03DANAHER : DHR) Insider Makes Significant Share Sale
MT
08/02INSIDER TRENDS : Insider 90-Day Selling Trend Prolonged at Danaher Corp
MT
07/28INSIDER TRENDS : Insider at Danaher Corp Acquires Stock Via Option/Derivative Se..
MT
07/27DANAHER : Unit, Cytiva Team Up to Invest $1.5 Billion to Expand Manufacturing Ca..
MT
07/27CYTIVA : and Pall Corporation investing 1.5 billion USD over two years to meet g..
PR
07/26DANAHER : Four Sustainability Kaizens Add Up to Savings
PU
07/26DANAHER CORP /DE/ : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
07/26DANAHER : Beckman Coulter to Distribute BNP Cardiac Assay to Customers
PR
07/23DANAHER : Goldman Sachs Adjusts Danaher's Price Target to $320 from $280, Keeps ..
MT
07/23DANAHER : JPMorgan Adjusts Danaher's Price Target to $310 from $280, Keeps Overw..
MT
More news
Financials (USD)
Sales 2021 28 653 M - -
Net income 2021 6 160 M - -
Net Debt 2021 13 539 M - -
P/E ratio 2021 36,5x
Yield 2021 0,29%
Capitalization 218 B 218 B -
EV / Sales 2021 8,09x
EV / Sales 2022 7,55x
Nbr of Employees 68 000
Free-Float 74,2%
Chart DANAHER CORPORATION
Duration : Period :
Danaher Corporation Technical Analysis Chart | DHR | US2358511028 | MarketScreener
Technical analysis trends DANAHER CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 23
Last Close Price 302,33 $
Average target price 313,63 $
Spread / Average Target 3,74%
EPS Revisions
Managers and Directors
Rainer M. Blair President, Chief Executive Officer & Director
Matthew R. McGrew Chief Financial Officer & Executive Vice President
Steven M. Rales Chairman
Jose Carlos GutiÚrrez Ramos Chief Science Officer & Senior Vice President
Brian W. Ellis Senior Vice President & General Counsel
Sector and Competitors